Get started
Author

Lyndsey Dugan

Observed names: Dugan, Lyndsey, L. Dugan
OpenAlex ID: A5079947492
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
2016 · Howard I. Scher, Ryon P. Graf, et al. · European Urology · 186
PDF
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2017 · Howard I. Scher, Ryon P. Graf, et al. · Cancer Research · 136
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
2016 · Archana Anantharaman, Terence Friedlander, et al. · BMC Cancer · 105
PDF
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2017 · Daniel J. Boffa, Ryon P. Graf, et al. · Cancer Epidemiology Biomarkers & Prevention · 71
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer
2019 · Simpa S. Salami, Udit Singhal, et al. · JCO Precision Oncology · 32
Androgen receptor expression on circulating tumor cells in metastatic breast cancer
2017 · Takeo Fujii, James M. Reuben, et al. · PLoS ONE · 22
PDF
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
2016 · Archana Anantharaman, Terence W. Friedlander, et al. · Journal of Clinical Oncology · 13
AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.
2016 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 5
CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen ecreptor signaling (AR Tx) and taxane (T) systemic therapies.
2016 · Howard I. Scher, Adam Jendrisak, et al. · Journal of Clinical Oncology · 4
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.
2016 · Archana Anantharaman, Terence W. Friedlander, et al. · Journal of Clinical Oncology · 4
Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.
2016 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 4
PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study
2016 · R. Graf, D. Lu, et al. · Annals of Oncology · 1
Abstract 496: Androgen receptor expression on circulating tumor cells in metastatic breast cancer
2016 · Takeo Fujii, Yipeng Wang, et al. · Cancer Research · 1
Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.
2016 · Daniel J Boffa, Jorge J. Nieva, et al. · Journal of Clinical Oncology · 1
Characterization of programmed cell death-1 ligand (PD-L1) expression in circulating tumor cells (CTCs) of lung cancer
2016 · Rachel Krupa, David Lu, et al. · Journal of Thoracic Oncology · 1
PDF
Clinical validation of CTC subtype frequency to prognosis OS in mCRPC patients.
2016 · Ryan Vance Dittamore, Jessica Louw, et al. · Journal of Clinical Oncology · 1
Data from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Data from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023 · Howard I. Scher, Ryon P. Graf, et al.
Supplementary Methods & Figures S1-S5 from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023 · Howard I. Scher, Ryon P. Graf, et al.
Figure S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Figure S2 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Table S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Figure S3 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Figure S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
PDF
Table S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
PDF
Works count: 36
Citation count: 587
H-index: 7
I10-index: 7
Year
Topic
Type